

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Franck J. BARRAT, et al.

Application No.: Unknown

Filed: Herewith

For: REGULATORY T CELLS;
METHODS

Examiner: Unknown

Art Unit: Unknown


Conf. No.: Unknown

"Express mailing" mailing label number EL 982 850 964 US
Date of Deposit: October 14, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

by:


MELANIE LYONS

INFORMATION DISCLOSURE STATEMENT

Honorable Sir:

The materials as listed in the attached Form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB/08 listing references AA-AW. Copies of all documents cited on Form PTO/SB/08 are available in the file of the parent patent application Ser. No. 09/970,446.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence. Applicants request that the Examiner fully consider the art cited in the attached Form PTO/SB/08. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe that no fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: October 14, 2003

By:



Tom Brody

Registration No.: 46,433

Patent Agent for Applicants

Customer No. 28008

DNA Research, Inc.

901 California Avenue

Palo Alto, CA 94304-1104

Telephone (Switchboard): (650) 496-6400

Telephone No. (Direct): (650) 496-1244

Facsimile No.: (650) 496-1200

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
				Application Number	
				Filing Date	Herewith
				First Named Inventor	Franck J. BARRAT
				Art Unit	
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	DX01177B

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ **Date Considered** _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
(Use as many sheets as necessary)				Filing Date	Herewith
				First Named Inventor	Franck J. BARRAT
				Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	DX01177B

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AB	M. HELOISA BLOTTA, et al., <u>J Immunol</u> , 158(12):5589-5595, June 15, 1997. "Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes"	
	AC	FRANK BRIDOUX, et al., <u>J Exp Med</u> , 185(10):1769-1775, May 19, 1997. "Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines"	
	AD	JAN BUER, et al., <u>J Exp Med</u> , 187(2):177-183, January 19, 1998. "Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells energized in vivo"	
	AE	NITYA G. CHAKRABORTY, et al., <u>J Immunol</u> , 162(9):5576-5583, May 1, 1999. "Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines"	
	AF	RONGBING CHEN, et al., <u>J Immunol</u> , 164(2):825-832, January 15, 2000. Glucocorticoids inhibit calcium- and calcineurin-dependent activation of the human IL-4 promoter"	
	AG	DANIELE D'AMBROSIO, et al., <u>J Clin Invest</u> , 101(1):252-262, January 1, 1998. "Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene"	
	AH	KAROLIEN DE BOSSCHER, et al., <u>Proc Natl Acad Sci U S A</u> , 94(25):13504-13509, December 9, 1997. "Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation"	
	AI	HERVE GROUX, et al., <u>Nature</u> , 389(6652):737-742, October 16, 1997. "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis"	
	AJ	GIANDOMENICA IEZZI, et al., <u>Eur J Immunol</u> , 29(12):4092-4101, December 1999. "The interplay between the duration of TCR and cytokine signaling determines T cell polarization"	
	AK	MICHAEL KARIN, <u>Cell</u> , 93(4):487-490, May 15, 1998. "New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable?"	
	AL	UI YEN KHOO, et al., <u>J Immunol</u> , 158(8):3626-3634, April 15, 1997. "CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens."	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
<i>(Use as many sheets as necessary)</i>				Filing Date	Herewith
				First Named Inventor	Franck J. BARRAT
				Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	DX01177B

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	FRANK MATTNER, et al., <u>Eur J Immunol</u> , 30(2):498-508, February 2000. "Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3)"	
	AN	CARLA MILLER, et al., <u>J Exp Med</u> , 190(1):53-64, July 5, 1999. "Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms <i>in vivo</i> "	
	AO	ANNE O'GARRA, <u>Immunity</u> , 8(3):275-283, March 1998. "Cytokines induce the development of functionally heterogeneous T helper cell subsets"	
	AP	LORENZO PIEMONTI, et al., <u>J Immunol</u> , 164(9):4443-4451, May 1, 2000. "Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells"	
	AQ	FRANCISCO RAMIREZ, et al., <u>J Immunol</u> , 156(7):2406-2412, April 1, 1996. "Glucocorticoids promote a TH2 cytokine response by CD4+ T cells <i>in vitro</i> "	
	AR	DAVID F. RICHARDS, et al., <u>Eur J Immunol</u> , 30(8):2344-2354, August 2000. "Glucocorticoids drive human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4, IL-5 and IL-13 production"	
	AS	CHAO-ZHONG SONG, et al., <u>Proc Natl Acad Sci U S A</u> , 96(21):11776-11781, October 12, 1999. "Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3"	
	AT	PEDRO L. VIEIRA, et al., <u>J Immunol</u> , 161(10):5245-5251, November 15, 1998. "Glucocorticoids inhibit bioactive IL-12p70 production by <i>in vitro</i> -generated human dendritic cells without affecting their T cell stimulatory potential"	
	AU	JEROEN VISSER, et al., <u>Blood</u> , 91(11):4255-4264, June 1, 1998. "Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids <i>in vitro</i> "	
	AV	THOMAS WILCKENS and ROEL DE RIJK, <u>Immunol Today</u> , 18(9):418-424, September 1997. "Glucocorticoids and immune function: unknown dimensions and new frontiers"	
	AW	JUNN YANAGISAWA, et al., <u>Science</u> , 283(5406):1317-1321, February 26, 1999. "Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators"	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.